Related Experiment Video
Updated: Nov 5, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Can biosimilar products be interchangeable? Pharmaceutical perspective in the implementation of biosimilars in
José Cleberson Santos Soares1, Iago Dillion Lima Cavalcanti1, Juliana Lúcia de Albuquerque Vasconcelos2
1Department of Biological Sciences - Universidade Federal de Pernambuco - UFPE, Recife, Brazil.
Objective:
To evaluate the safety in the interchangeability of biosimilar products approved for cancer treatment from a pharmaceutical perspective.
Methods:
A literature review was carried out using the descriptors "Biosimilar", "Oncology Therapy", "Interchangeable drugs" and "Biological Products", in the Sciencedirect, MEDLINE, and CAPLUS databases.
Results:
Fifty-one articles were selected, which addressed the importance of establishing standards that prove the efficacy and safety of biosimilars with reference products, as well as the growing interest of the pharmaceutical industry in the development of biosimilars and the impact on costs and changes in the perspective of the treatment of cancer patients.
Conclusions:
As they are large and complex molecules, it is impossible to obtain identical copies of their reference products, which generates conflicts and concerns on the part of the pharmaceutical class regarding the safety in the interchangeability of these products, highlighting the importance of pharmacovigilance in this process.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Bioequivalence: Overview
Bioequivalence of Drugs: Drugs with Multiple Indications
Pharmaceutical Equivalents
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Equivalence: In Vitro and In Vivo Bioequivalence

